Single-blind, randomised, placebo-controlled two-part study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single oral escalating doses and repeat doses of GSK729327 in healthy volunteers.

Trial Profile

Single-blind, randomised, placebo-controlled two-part study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single oral escalating doses and repeat doses of GSK729327 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2009

At a glance

  • Drugs GSK 729327 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2009 Actual patient number (79) added as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top